EXAS Hits 52-Week High Amid Acquisition Buzz
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 Nov 25
Source: Benzinga
Shares of Exact Sciences (EXAS.O) surged by 28% today, reaching a new 52-week high following reports of a potential acquisition by Abbott Laboratories (ABT). The stock's impressive performance reflects growing investor confidence as negotiations between the two companies progress, although delays in finalizing the deal are possible. Exact Sciences, recognized for its Cologuard colon cancer test, has also raised its 2025 revenue guidance to $3.235 billion, further bolstering its market position and attracting acquisition interest. Analysts suggest that any takeover would necessitate a valuation exceeding $100 per share, indicating a significant premium over current trading levels.
Analyst Views on EXAS
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 100.20 USD with a low forecast of 78.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
1 Buy
19 Hold
0 Sell
Hold
Current: 102.300
Low
78.00
Averages
100.20
High
105.00
Current: 102.300
Low
78.00
Averages
100.20
High
105.00
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
